SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The turnover is pegged at Rs. 106.41 millions for the June 2022 quarter. The mentioned figure indicates a rise of about 57.53% as against Rs. 67.55 millions during the year-ago period.The Net Loss for the quarter ended June 2022 is Rs. -81.36 millions as compared to Net Loss of Rs. -94.24 millions of corresponding quarter ended June 2021 Operating profit Margin for the quarter ended June 2022 improved to -61.39% as compared to -64.96% of corresponding quarter ended June 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 106.41 67.55 57.53 106.41 67.55 57.53 597.03 537.00 11.18
Other Income 1.29 0.30 330.00 1.29 0.30 330.00 11.56 6.21 86.15
PBIDT -61.39 -64.96 -5.50 -61.39 -64.96 -5.50 -328.39 -169.56 93.67
Interest 3.04 15.12 -79.89 3.04 15.12 -79.89 53.91 62.79 -14.14
PBDT -64.43 -80.08 -19.54 -64.43 -80.08 -19.54 -382.30 -232.35 64.54
Depreciation 16.93 14.16 19.56 16.93 14.16 19.56 62.97 51.24 22.89
PBT -81.36 -94.24 -13.67 -81.36 -94.24 -13.67 -445.27 -283.59 57.01
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -81.36 -94.24 -13.67 -81.36 -94.24 -13.67 -445.27 -283.59 57.01
Equity 215.61 215.61 0.00 215.61 215.61 0.00 215.61 196.21 9.89
PBIDTM(%) -57.69 -96.17 -40.01 -57.69 -96.17 -40.01 -55.00 -31.58 74.20

Krebs Biochem.&Inds Share Price

60.90 -0.12 (-0.20%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×